Anticoagulation is the most-important intervention to prevent stroke in patients with atrial
fibrillation (AF). Despite a lower point prevalence of AF in Asian communities and Asian …

Abstract Background Direct oral anticoagulants (DOACs) are indicated for the prevention of
stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation. While no …

Background: Clinical trials have shown direct oral anticoagulants (DOACs) are at least as
effective and safe as warfarin for risk of stroke/systemic embolism (S/SE) and major bleeding …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Aims: Observational studies of various dose levels of direct oral anticoagulants (DOACs) for
patients with atrial fibrillation (AF) found that a high proportion of patients received a dose …

Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …

Background Direct oral anticoagulants (DOACs) are commonly used to prevent stroke and
systemic embolism in patients with atrial fibrillation (AF). However, studies into their …

Background The perceived risk of serious bleeding is an obstacle to the use of oral
anticoagulation in East Asia. The efficacy and safety of apixaban in East Asian patients with …

Background: The meta-analysis of randomized controlled trials has illustrated that the
efficacy of low-dose non-vitamin K antagonist oral anticoagulants is inferior compared with …

Rivaroxaban has emerged as a potential alternative to warfarin for the prevention of
thromboembolism in patients with atrial fibrillation (AF). However, there has been concern …